Vaborbactam (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Vaborbactam" in English language version.

refsWebsite

Global rank English rank

4^th place

2^nd place

1^st place

195^th place

302^nd place

447^th place

338^th place

11^th place

8^th place

doi.org

Hecker SJ, Reddy KR, Totrov M, Hirst GC, Lomovskaya O, Griffith DC, et al. (May 2015). "Discovery of a Cyclic Boronic Acid β-Lactamase Inhibitor (RPX7009) with Utility vs Class A Serine Carbapenemases". Journal of Medicinal Chemistry. 58 (9): 3682–92. doi:10.1021/acs.jmedchem.5b00127. PMID 25782055.
Burgos RM, Biagi MJ, Rodvold KA, Danziger LH (October 2018). "Pharmacokinetic evaluation of meropenem and vaborbactam for the treatment of urinary tract infection". Expert Opinion on Drug Metabolism & Toxicology. 14 (10): 1007–1021. doi:10.1080/17425255.2018.1511702. PMID 30106599. S2CID 52006261.
Queenan AM, Bush K (July 2007). "Carbapenemases: the versatile beta-lactamases". Clinical Microbiology Reviews. 20 (3): 440–58, table of contents. doi:10.1128/CMR.00001-07. PMC 1932750. PMID 17630334.
Lamotte-Brasseur J, Knox J, Kelly JA, Charlier P, Fonzé E, Dideberg O, Frére JM (December 1994). "The structures and catalytic mechanisms of active-site serine beta-lactamases". Biotechnology & Genetic Engineering Reviews. 12 (1): 189–230. doi:10.1080/02648725.1994.10647912. PMID 7727028.
Griffith DC, Loutit JS, Morgan EE, Durso S, Dudley MN (October 2016). "Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of the β-Lactamase Inhibitor Vaborbactam (RPX7009) in Healthy Adult Subjects". Antimicrobial Agents and Chemotherapy. 60 (10): 6326–32. doi:10.1128/AAC.00568-16. PMC 5038296. PMID 27527080.

Hecker SJ, Reddy KR, Totrov M, Hirst GC, Lomovskaya O, Griffith DC, et al. (May 2015). "Discovery of a Cyclic Boronic Acid β-Lactamase Inhibitor (RPX7009) with Utility vs Class A Serine Carbapenemases". Journal of Medicinal Chemistry. 58 (9): 3682–92. doi:10.1021/acs.jmedchem.5b00127. PMID 25782055.
Burgos RM, Biagi MJ, Rodvold KA, Danziger LH (October 2018). "Pharmacokinetic evaluation of meropenem and vaborbactam for the treatment of urinary tract infection". Expert Opinion on Drug Metabolism & Toxicology. 14 (10): 1007–1021. doi:10.1080/17425255.2018.1511702. PMID 30106599. S2CID 52006261.
Queenan AM, Bush K (July 2007). "Carbapenemases: the versatile beta-lactamases". Clinical Microbiology Reviews. 20 (3): 440–58, table of contents. doi:10.1128/CMR.00001-07. PMC 1932750. PMID 17630334.
Lamotte-Brasseur J, Knox J, Kelly JA, Charlier P, Fonzé E, Dideberg O, Frére JM (December 1994). "The structures and catalytic mechanisms of active-site serine beta-lactamases". Biotechnology & Genetic Engineering Reviews. 12 (1): 189–230. doi:10.1080/02648725.1994.10647912. PMID 7727028.
Griffith DC, Loutit JS, Morgan EE, Durso S, Dudley MN (October 2016). "Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of the β-Lactamase Inhibitor Vaborbactam (RPX7009) in Healthy Adult Subjects". Antimicrobial Agents and Chemotherapy. 60 (10): 6326–32. doi:10.1128/AAC.00568-16. PMC 5038296. PMID 27527080.

Burgos RM, Biagi MJ, Rodvold KA, Danziger LH (October 2018). "Pharmacokinetic evaluation of meropenem and vaborbactam for the treatment of urinary tract infection". Expert Opinion on Drug Metabolism & Toxicology. 14 (10): 1007–1021. doi:10.1080/17425255.2018.1511702. PMID 30106599. S2CID 52006261.